Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ServiceUpdated on 5 September 2025

专业的生物和化学药物及衍生物标准品定制合成与分析检验检定

志平 刘

产品开发总监,主任级高级研究员,董事长特别代理 at 中国标准药物集团有限公司

广东, China

About

STD PHARM has over 1,000,000 products in 10 application area, including: Pharmaceutical Impurities, Pesticide and Veterinary Pharmaceutical Residues, Isotopes, Essence and Pigment, Criminal Justice Medicine, Natural pharmaceutical Extraction, Cosmetic, Environmental Protection, Food safety, Industrial Auxiliary Materials. Certificate of Analysis (COA) will be provided for all these products which characterized using HPLC/GC, MS, HNMR, synthetic route, spectrum analysis and other testing (CNMR, FNMR, COSY, NOESY, DEPT, HMBC, HMQC, HSQC, IR, UV, QNMR, TGA, elemental analysis, etc. ) as requested spectra by our clients. And STD Promises to return or exchange the goods to solve the problem as quickly as possible if any quality problem is found within the contractual period. STD has inventory in both China and the United States to ensure the fastest delivery for customers.

中国标准药物集团有限公司可以提供超过1,000,000种化合物,产品应用领域涵盖10个大类,包括:药物化学杂质、农药兽药残留、同位素标记物、香精色素、刑事司法医学、天然药物提取、化妆品、环境保护、食品安全、工业辅料等。STD品牌提供的每一种化合物均会提供有检测赋值的分析证书(COA)、高效液相色谱/气相色谱(HPLC/GC)、质谱(MS)、核磁氢谱(HNMR),以及附属的合成路线、图谱解析或客户要求的其他测试如核磁(CNMR、FNMR、QNMR等)、元素分析、TGA、IR、UV等等。如在合同规定期内发现确认存在产品质量的相关问题,STD承诺尽快换货以解决问题或退货。STD集团在中国和美国都有大型仓储中心,现货库存种类丰富,数量充足。无论您身处何处,我们都能迅速满足您的需求,为您提供全方位、高效的服务。

Type

  • Professional Services

Similar opportunities

  • Project

    寿仙谷对外招商项目

    • No
    • None
    • Private Project
    • Food Processing
    • Project Planning
    • Financial Services
    • Professional Services
    • Agriculture, Food and Rural Development

    LIN JIN

    商务部副总监 at 寿仙谷药业

    杭州, China

  • Project

    东曜药业(1875.HK)项目推介

    • Yes
    • IPO
    • Bio-Tech
    • Technology
    • Hedge Funds
    • Manufacturing
    • Private Project
    • R&D Cooperation
    • Fund Management
    • Wealth Management
    • Financial Services
    • Open for Negotiation
    • Minority Shareholdings
    • 50,000,001 USD or above
    • Institutional Investment
    • Feasibility Study Completed
    • Private Equity & Venture Capital

    灵鸽 刘

    投资者关系副总监 at 东曜药业有限公司

    苏州, China

  • Project

    元素驱动创新高性能环保材料为全球生态文明贡献中国方案

    • Yes
    • Series A
    • Bio-Tech
    • Operations
    • Technology
    • Manufacturing
    • IT Consulting
    • Private Project
    • R&D Cooperation
    • Financial Services
    • Open for Negotiation
    • Open for negotiation
    • Minority Shareholdings
    • 50,000,001 USD or above
    • 50,000,001 USD or above
    • Institutional Investment
    • Information Technology Services
    • Plantation, Fishery and Forestry
    • Agriculture, Food and Rural Development

    旻昊 刘

    董事长兼CEO at 元素驱动

    杭州, China